Key terms
About ARWR
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ARWR news
Yesterday
7:03am ET
Athira Pharma appoints Javier San Martin as Chief Medical Officer
Apr 08
6:37am ET
Arrowhead Pharmaceuticals (ARWR) Receives a Buy from Piper Sandler
Apr 07
9:12am ET
Arrowhead announces new Phase 2 SHASTA-2 study of plozasiran in SHTG
Mar 25
8:06am ET
Arrowhead begins EAP to avail plozasiran outside of trials for patients with FCS
Mar 14
6:40am ET
Analysts’ Top Healthcare Picks: Edwards Lifesciences (EW), Arrowhead Pharmaceuticals (ARWR)
Mar 08
5:58pm ET
Arrowhead CFO Myszkowski sells 40,000 common shares
Mar 08
7:35am ET
Arrowhead doses first patients in ARO-DM1 trial
Feb 28
1:28pm ET
Arrowhead rumor mentioned in Betaville blog
Feb 22
6:22am ET
Arrowhead Pharmaceuticals Appoints Dr. Hongbo Lu to Board
Feb 08
12:25pm ET
Buy Rating Affirmed for Arrowhead Pharmaceuticals with Strong Growth Projections and Pipeline Potential
Feb 08
9:08am ET
Arrowhead price target raised to $55 from $50 at B. Riley
Feb 08
8:10am ET
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Arrowhead Pharmaceuticals (ARWR)
Feb 07
4:55pm ET
Strategic Developments and Financial Strength Underpin Buy Rating for Arrowhead Pharmaceuticals
Feb 07
8:30am ET
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Waters (WAT) and Bristol-Myers Squibb (BMY)
Feb 07
8:17am ET
Piper Sandler Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
Feb 07
7:32am ET
RBC Capital Keeps Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
Feb 07
7:28am ET
Arrowhead Pharmaceuticals: Strategic Cost-Cutting and Resource Allocation to Bolster Commercial Transition
Feb 07
7:15am ET
Arrowhead price target lowered to $75 from $78 at UBS
Feb 07
6:40am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Edwards Lifesciences (EW) and Doximity (DOCS)
Feb 07
6:36am ET
Arrowhead price target raised to $34 from $33 at Citi
Feb 06
4:04pm ET
Arrowhead reports Q1 EPS ($1.24), consensus (82c)
Jan 30
1:15pm ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Jan 30
10:55am ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Jan 18
5:37am ET
Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential
No recent news articles are available for ARWR
No recent press releases are available for ARWR
ARWR Financials
Key terms
Ad Feedback
ARWR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ARWR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
